There is something to the resumption that FDA does

There is something to the resumption that FDA does not like antibody-antigen methods. Here's a fact, not an opinion. Entities have presented 77 applications for EUA using some form of antigen-antibody methodology. Exactly one of these applications has been approved. One in 77.

Now, I would have to suspend my disbelief to buy into the current status, that is all 76 of the not approved applications are flawed beyond modest or moderate edit. Sooner rather than later one of these 76 will go public and point fingers. MDMA will also go public.

I have provided you and others with my many years of experience dealing directly with the FDA. I am just one of thousands. So I am not alone and I am not surprised that the EUA process has been bastardized. The FDA picks winners and losers. Winners are almost always big pharma. Losers are almost always small entrepreneurial and first timer companies. DECN has been through this process with the FDA several times so they do not fall into first time categories. And the DECN methodology, despite the protests of Always, is not an antigen-antibody method.

I keep coming back to your entry on to this message board. You told us all that you were the consultant to the industry. Turns out you trade stocks. Nothing wrong with that, except for the masquerade, but the consultant to the industry would know all about how the FDA practices politics. And Trump is just the guy to end this practice.

But before he does, one or more of these purgatory companies will have to step up and spill the beans. Then Gottleib, the consummate politician, will step up and tell his story. Sit back and learn.